http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 05 Jun 2026 07:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Seres+Therapeutics%2C+Inc.++For%3A+Jun+02/26608285.html si-local-file:///var/storage/secattach/20260605/26608285.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Seres+Therapeutics%2C+Inc.++For%3A+Jun+02/26608285.html Fri, 05 Jun 2026 07:05:00 -0400 MCRB O.23136602 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Seres+Therapeutics%2C+Inc.++For%3A+Jun+02/26608285.html si-local-file:///var/storage/secattach/20260605/26608285.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Seres+Therapeutics%2C+Inc.++For%3A+Jun+02/26608285.html Fri, 05 Jun 2026 07:05:00 -0400 MCRB O.23136602 http://www.streetinsider.com/Corporate+News/Seres+Therapeutics+secures+%2425+million+from+Nestle+deal%2C+cuts+lease+costs/26608266.html <p>Seres Therapeutics Inc. (NASDAQ: MCRB) announced two transactions designed to strengthen its balance sheet and extend its operating cash runway into the first quarter of 2027, according to a company press release.</p><p>The biotechnology company amended its asset purchase agreement with Nestlé Health Science, which will pay Seres $25 million in two equal installments in July and October 2026. The payment represents a buyout of potential future milestone payments tied to net sales of VOWST, a microbiome-based therapeutic that Seres sold to Nestlé Health Science in 2024.</p><p>Seres also restructured its lease agreement for its facility at 101 CambridgePark Drive in Cambridge, http://www.streetinsider.com/Corporate+News/Seres+Therapeutics+secures+%2425+million+from+Nestle+deal%2C+cuts+lease+costs/26608266.html Fri, 05 Jun 2026 07:00:54 -0400 MCRB http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html <p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones</em></p> <p align="center"><em>Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability</em></p> <p align="center"><em>Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month</em></p> <p>CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html Fri, 05 Jun 2026 07:00:00 -0400 A.06822034 A.32727947 MCRB O.00048394 O.20026344 O.23136602 http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html <p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones</em></p> <p align="center"><em>Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability</em></p> <p align="center"><em>Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month</em></p> <p>CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html Fri, 05 Jun 2026 07:00:00 -0400 A.06822034 A.32727947 MCRB O.00048394 O.20026344 O.23136602 http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html <p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones</em></p> <p align="center"><em>Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability</em></p> <p align="center"><em>Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month</em></p> <p>CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html Fri, 05 Jun 2026 07:00:00 -0400 A.06822034 A.32727947 MCRB O.00048394 O.20026344 O.23136602 http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html <p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones</em></p> <p align="center"><em>Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability</em></p> <p align="center"><em>Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month</em></p> <p>CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html Fri, 05 Jun 2026 07:00:00 -0400 A.06822034 A.32727947 MCRB O.00048394 O.20026344 O.23136602 http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html <p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones</em></p> <p align="center"><em>Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability</em></p> <p align="center"><em>Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month</em></p> <p>CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html Fri, 05 Jun 2026 07:00:00 -0400 A.06822034 A.32727947 MCRB O.00048394 O.20026344 O.23136602 http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html <p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones</em></p> <p align="center"><em>Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability</em></p> <p align="center"><em>Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month</em></p> <p>CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html Fri, 05 Jun 2026 07:00:00 -0400 A.06822034 A.32727947 MCRB O.00048394 O.20026344 O.23136602 http://www.streetinsider.com/Globe+Newswire/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html <p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones</em></p> <p align="center"><em>Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability</em></p> <p align="center"><em>Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month</em></p> <p>CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the http://www.streetinsider.com/Globe+Newswire/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html Fri, 05 Jun 2026 07:00:00 -0400 A.06822034 A.32727947 MCRB O.00048394 O.20026344 O.23136602 http://www.streetinsider.com/Globe+Newswire/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html <p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones</em></p> <p align="center"><em>Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability</em></p> <p align="center"><em>Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month</em></p> <p>CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the http://www.streetinsider.com/Globe+Newswire/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html Fri, 05 Jun 2026 07:00:00 -0400 A.06822034 A.32727947 MCRB O.00048394 O.20026344 O.23136602 http://www.streetinsider.com/Globe+Newswire/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html <p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones</em></p> <p align="center"><em>Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability</em></p> <p align="center"><em>Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month</em></p> <p>CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the http://www.streetinsider.com/Globe+Newswire/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html Fri, 05 Jun 2026 07:00:00 -0400 A.06822034 A.32727947 MCRB O.00048394 O.20026344 O.23136602 http://www.streetinsider.com/Globe+Newswire/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html <p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones</em></p> <p align="center"><em>Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability</em></p> <p align="center"><em>Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month</em></p> <p>CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the http://www.streetinsider.com/Globe+Newswire/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html Fri, 05 Jun 2026 07:00:00 -0400 A.06822034 A.32727947 MCRB O.00048394 O.20026344 O.23136602 http://www.streetinsider.com/Globe+Newswire/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html <p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones</em></p> <p align="center"><em>Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability</em></p> <p align="center"><em>Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month</em></p> <p>CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the http://www.streetinsider.com/Globe+Newswire/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html Fri, 05 Jun 2026 07:00:00 -0400 A.06822034 A.32727947 MCRB O.00048394 O.20026344 O.23136602 http://www.streetinsider.com/Globe+Newswire/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html <p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones</em></p> <p align="center"><em>Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability</em></p> <p align="center"><em>Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month</em></p> <p>CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the http://www.streetinsider.com/Globe+Newswire/Seres+Therapeutics+Announces+Two+Transactions+to+Strengthen+Balance+Sheet%2C+Reduce+On-Going+Lease+Costs+and+Extend+Projected+Operating+Cash+Runway+Well+Into+the+First+Quarter+of+2027/26608262.html Fri, 05 Jun 2026 07:00:00 -0400 A.06822034 A.32727947 MCRB O.00048394 O.20026344 O.23136602 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+30/26584288.html si-local-file:///var/storage/secattach/20260601/26584288.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+30/26584288.html Mon, 01 Jun 2026 16:33:00 -0400 MCRB O.23136602 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+30/26584288.html si-local-file:///var/storage/secattach/20260601/26584288.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+30/26584288.html Mon, 01 Jun 2026 16:33:00 -0400 MCRB O.23136602 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Seres+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Young+Teresa+L./26521367.html si-local-file:///var/storage/secattach/20260519/26521367.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Seres+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Young+Teresa+L./26521367.html Tue, 19 May 2026 16:16:00 -0400 MCRB O.23136602 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Seres+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Young+Teresa+L./26521367.html si-local-file:///var/storage/secattach/20260519/26521367.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Seres+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Young+Teresa+L./26521367.html Tue, 19 May 2026 16:16:00 -0400 MCRB O.23136602 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+DesRosier+Thomas/26521022.html si-local-file:///var/storage/secattach/20260519/26521022.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+DesRosier+Thomas/26521022.html Tue, 19 May 2026 16:05:00 -0400 MCRB O.23136602 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+DesRosier+Thomas/26521022.html si-local-file:///var/storage/secattach/20260519/26521022.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+DesRosier+Thomas/26521022.html Tue, 19 May 2026 16:05:00 -0400 MCRB O.23136602 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+Brady+Kelly/26521024.html si-local-file:///var/storage/secattach/20260519/26521024.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+Brady+Kelly/26521024.html Tue, 19 May 2026 16:05:00 -0400 MCRB O.23136602 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+Brady+Kelly/26521024.html si-local-file:///var/storage/secattach/20260519/26521024.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+Brady+Kelly/26521024.html Tue, 19 May 2026 16:05:00 -0400 MCRB O.23136602 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+Henn+Matthew+R/26521027.html si-local-file:///var/storage/secattach/20260519/26521027.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+Henn+Matthew+R/26521027.html Tue, 19 May 2026 16:05:00 -0400 MCRB O.23136602 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+Henn+Matthew+R/26521027.html si-local-file:///var/storage/secattach/20260519/26521027.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Seres+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+Henn+Matthew+R/26521027.html Tue, 19 May 2026 16:05:00 -0400 MCRB O.23136602